Report Highlights

The United States in the Global IBD Treatment Supply Chain

The United States is the largest end market for inflammatory bowel disease biologics, accounting for well over half of global advanced-therapy revenue. Domestic drug substance capacity is concentrated in a handful of high-volume campuses, including AbbVie's North Chicago site and Amgen's Thousand Oaks and Puerto Rico operations. Finished-dose fill-finish remains heavily offshore, with Ireland and Switzerland supplying most injectable imports, while total U.S. pharmaceutical imports exceed USD 200 billion annually.

On the export side, the United States supplies biologic drug substance and bulk intermediates to Europe and Asia-Pacific, while importing autoinjectors, prefilled syringes and device components from Germany and Mexico. Biosimilar infliximab and ustekinumab are increasingly produced at Korean plants in Songdo and Incheon, which ship via Los Angeles and Long Beach into U.S. distribution. Puerto Rico functions as a tax-advantaged processing hub, linking U.S. formulation to global distribution networks.

Growth Drivers for IBD Treatment in the United States

Prevalence is the foundational driver, with the Crohn's and Colitis Foundation estimating roughly three million Americans living with IBD. Shifting maintenance dosing toward subcutaneous and oral options, including AbbVie's Skyrizi and Rinvoq, Johnson & Johnson's Tremfya, and Eli Lilly's Omvoh, moves volume into home-delivery channels. That transition drives demand for autoinjector and prefilled-syringe capacity, creating fresh contract-fill volume for U.S. and Irish sites.

Onshoring is the second major driver, as drug makers pledge large domestic investments to reduce tariff exposure. Johnson & Johnson's biologics plant in Wilson, North Carolina, and AbbVie's expansion of its North Chicago operations are shifting drug substance production toward U.S. soil. Biosimilar competition from Celltrion and Samsung Bioepis, meanwhile, expands import substitution, with Korean drug substance displacing originator supply in infusion centers.

Supply Chain Risks and Trade Barriers in U.S. IBD Treatment

Section 232 pharmaceutical tariff investigations and the 2025 U.S.-EU framework, which caps tariffs on EU-origin pharmaceuticals at 15 percent, leave Irish biologic imports exposed to policy shifts. Active pharmaceutical ingredient dependence compounds the risk, since China and India supply a large share of small-molecule intermediates used in oral therapies such as ozanimod and etrasimod. Any tariff escalation on those intermediates raises landed cost before finished goods reach U.S. pharmacies.

Cold-chain logistics are the second vulnerability, because biologic drug substance and finished autoinjectors require temperature-controlled transport between Dublin, Cork, Puerto Rico and U.S. distribution centers. Sterile fill-finish capacity is tight, and any single-site shutdown forces expedited air freight at significant cost. Currency exposure also matters, as Korean biosimilar pricing in won and Irish cost bases in euro shift U.S. dollar margins for distributors each quarter.

Trade and Investment Opportunities for IBD Therapies in the U.S.

Contract fill-finish and autoinjector assembly represent the most immediate opening, as onshoring mandates push originators to qualify domestic partners outside Ireland. Korean biosimilar developers holding FDA approvals for infliximab and ustekinumab are strong candidates for U.S. greenfield facilities that supply domestic distribution without tariff exposure. Foreign direct investment into North Carolina and Puerto Rico biologics clusters offers state incentive packages that materially reduce capital costs.

Export-oriented opportunities lie in Puerto Rico's free trade zone and USMCA-linked trade routes, where finished biosimilar doses can be re-exported to Canada and Mexico under preferential terms. Logistics hubs at Memphis and Louisville, anchored by FedEx and UPS air networks, serve as cold-chain gateways for pharmaceutical distribution. Specialty distributors building temperature-controlled cross-dock capacity near those hubs can capture next-day biologic delivery to infusion centers nationwide.

Market at a Glance

Leading Market Participants

• AbbVie
• Johnson & Johnson
• Takeda Pharmaceutical
• Eli Lilly and Company
• Pfizer
• Bristol Myers Squibb
• Amgen
• Celltrion
• Samsung Bioepis
• Teva Pharmaceuticals

Regulatory and Trade Policy Environment for IBD Treatments in the U.S.

FDA regulates IBD biologics through the Biologics License Application pathway, and biosimilars receive interchangeability designations that enable pharmacy-level substitution. The Inflation Reduction Act's Medicare negotiation program includes ustekinumab, with negotiated prices effective from 2026, reshaping Medicare drug economics. Section 232 pharmaceutical investigations and the U.S.-EU framework agreement set the tariff ceiling for EU-origin medicines at 15 percent.

USMCA governs duty-free treatment for qualifying pharmaceutical trade with Canada and Mexico, while Puerto Rico's Act 60 incentives support manufacturing investment on the island. Import classification under HTS chapter 30 determines duty treatment, and biologic drug substances face different customs rules from finished doses. Importers must document origin and classification for each product line to secure preferential treatment.

Supply Chain Outlook for IBD Treatment in the United States to 2032

Domestic drug substance capacity will expand as originators complete the Wilson, North Carolina and North Chicago projects, reducing the share of Irish-origin finished biologics entering U.S. distribution. Subcutaneous and oral formats gain share through 2032, shifting comparative advantage toward device assembly and small-molecule API supply chains concentrated in Asia.

Korean biosimilar suppliers will hold a larger share of infliximab and ustekinumab volume, pushing U.S. import flows from European originators toward Asian drug substance. Technology changes, including continuous manufacturing and single-use bioreactors, lower capital intensity and allow mid-sized U.S. contract manufacturers to enter biologics supply chains.